Navigation Links
7 Health Ventures Invests in Tulip Medical
Date:9/15/2008

HERZELIA, Israel, September 15 /PRNewswire/ -- 7 Health Ventures, a professional venture capital fund dedicated to investing in healthcare technologies and products, announced today it had joined a deferred closing of Tulip Medical's round A of financing. Dr. Dalia Megiddo, founder and managing partner at 7 Health Ventures, will join Tulip's board of directors.

Tulip Medical Ltd. is a medical device company that is developing the next generation solution for the worldwide overweight and obesity epidemic, focusing on the overweight and mild obese markets.

"The company's products address one of the biggest and most urgent problems the world is facing, which is often referred to as the epidemic of the 21st century" said Dr. Megiddo. "To date, all existing treatments fall short of providing a solution for the ever growing population of the overweight and obese. These solutions are either very aggressive, such as surgery, or very limited in their clinical benefits. Tulip's device has the potential of providing a very effective solution while being extremely safe and easy to use."

Tulip's flagship product is a unique orally taken biodegradable solution wherein patients will experience a long term feeling of satiety free of the severe complications associated with existing solutions. The company has developed a disposable medical device that is swallowed as a regular capsule. The device's mechanism of action is purely mechanical and does not involve any chemical activity.

Tulip was incorporated in Israel in August 2005 by Dr. Shimon Eckhouse, Active Chairman of the company and Doron Marco which serves as the company's CTO. The Company operates from its offices in Herzelia, Israel, and is managed by CEO Allon Reiter.

About 7 Health Ventures

7 Health Ventures is a professional venture capital fund which invests in technology companies developing medical technologies, products and services. The fund which launched its activity in September 2007 had invested in 4 companies thus far. 7 Health Ventures is operating from its offices in Herzelia, Israel with a representation in the bay area, California, and puts its primary focus on Israeli and Israeli-related companies.

For more information:

info@7healthventures.com,

http://www.7healthventures.com,

+972-9-9520214


'/>"/>
SOURCE 7 Health Ventures
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Tone Deafness Explained, from the Harvard Health Letter
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):